Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid

Three separate interventions will be undertaken with the primary outcome of improving pulse wave velocity. Initially, age and BMI-matched men and post-menopausal women, all with type 2 diabetes, will be treated with allopurinol (20 men, 20 women) for 6 months, in order to reduce serum uric acid (SUA) concentrations relative to placebo (10 men, 10 women). In a second intervention, dietary fructose will be restricted for a period of 6 months in type 2 diabetes (T2D) subjects who will maintain a stable weight (20 men, 20 women). In a third intervention, dietary fructose will be restricted for a period of 6 months in type 2 diabetes (T2D) subjects who will achieve a caloric deficit and weight reduction (20 men, 20 women). At the beginning and end of each of the studies, measures of arterial stiffness will be combined with assessments of endothelial function (flow-mediated dilation and insulin stimulated leg blood flow), measurements of systemic inflammation and oxidative stress.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus, Type 2; Hyperuricemia
• Intervention / Treatment: Other: Low-fructose diet, isocaloric; Drug: Allopurinol; Drug: Placebo; Other: Low-fructose, hypocaloric

Detailed Description

Sedentary, overweight and obese subjects diagnosed with T2D, ages 40-75 years old, will be recruited from the local community, via the University of Missouri's Endocrinology Clinic and the primary care clinics. During screening, and after consent, anthropometrics (waist circumference and body composition) will be obtained and fasting blood will be drawn for serum chemistries, A1c, complete blood count, liver and kidney function. Screening will also include completion of an oral glucose tolerance test with measurements of arterial stiffness and assessment of endothelial function. Following screening, eligible subjects will be assigned to one of the four groups (allopurinol, placebo, fructose restriction/isocaloric, or fructose restriction/hypocaloric). Allopurinol will be titrated to achieve a target dose of 300 mg/day. Along with placebo, this arm of the study is double-blinded. A separate group of men and women will be assigned to the isocaloric fructose-restriction study in which dietary fructose is replaced by starch and body weight is held constant. Lastly, a separate group of men and women will be assigned to the hypocaloric fructose-restriction in which baseline caloric intake will be reduced by 500 Calories/day while baseline intakes of protein and fat will remain constant. The subjects in these groups will not be blinded to the dietary treatment but the staff making measurements will be. Subjects in the four groups will be matched for age and BMI.

• Study Type: Interventional
• Enrollment (Actual): 34
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Missouri
    • Columbia, Missouri, United States, 65212
      • University of Missouri

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Men and women ages 40-75 years at randomization
• BMI between 25.1 and 50 kg/m2.
• Type 2 diabetes diagnosed > 3 months ago. Patients with T2D will be classified based on physician diagnosis.

Exclusion Criteria:

• serum uric acid < 5.5 mg/dL (for medication/allopurinol and isocaloric low-fructose diet arm)
• habitual diet containing low amount of sugars < 5% of total energy intake
• recent CVD event (stroke, heart failure hospitalization, revascularization or acute coronary event in the last 12 months).
• abnormal thyroid tests or chronic liver disease
• stage IV renal disease (GFR <30)
• hyperparathyroidism
• use of azathioprine
• active cancer
• autoimmune diseases
• excessive alcohol consumption (>14 drinks/week for men, >7 drinks/week for women)
• current tobacco use
• bodyweight change ≥10% within the last 6 months
• history of gout or uncontrolled hypertension
• A1C >10 % (only for medication/placebo arm)
• Pregnancy or lactation in women (or women not using contraceptives)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Low-fructose diet, isocaloric; Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose while maintaining baseline body weight.	Other: Low-fructose diet, isocaloric; 6 month of consumption a low fructose diet
Experimental: Allopurinol; Subjects assigned to this arm of the study will be treated for 6 months with allopurinol (max dose 300 mg)	Drug: Allopurinol; 6 months of allopurinol treatment with the goal of decreasing uric acid compared to control group; Other Names: Zyloprim
Placebo Comparator: Placebo; Subjects assigned to this arm will receive placebo	Drug: Placebo; 6 months of placebo treatment
Experimental: Low-fructose diet, hypocaloric; Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose with a 500 Calorie energy reduction.	Other: Low-fructose, hypocaloric; 6 month of consumption a low fructose diet with a 500 Calorie/day energy restriction

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Carotid Femoral Pulse Wave Velocity (cfPWV)	It is the gold standard non-invasive index of arterial stiffness. Transit time between carotid and femoral pressure waves is calculated using the foot-to-foot method. cfPWV is calculated as distance traveled by the pulse wave (i.e., femoral location-sternal notch minus sternal notch-carotid location) divided by pulse transit time. All the measurements will be done by the same blinded technician	This will be assessed at baseline and 6 months (final). The goal is to assess changes from baseline when compared to final time point.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Brachial Artery Flow Mediated Dilation (FMD)	Brachial artery FMD will be assessed at baseline and final. FMD is a measurement of conduit artery endothelial function. FMD is assessed immediately after each PWV measurement. Shear rate AUC until peak diameter is calculated as stimulus for FMD and used in covariate analysis as described. All measurements will be performed, under co-I supervision by the same blinded technician.	Baseline and 6 months (final). The goal is to assess changes from baseline when compared to final time point.
Insulin-stimulated Leg Blood Flow	We will perform a hyperinsulinemic euglycemic clamp to evaluate insulin-stimulated leg blood flow (to be assessed via Doppler ultrasound). Insulin will be infused at a constant rate to mimic postprandial insulin concentrations and glucose maintained at fasting values via a variable 20% dextrose infusion. Femoral artery blood flow will be assessed at the beginning and at end of the 60-minute insulin infusion, and data are presented as percent of change from pre-insulin infusion values.	The goal is to assess insulin stimulated responses in blood flow after 6 mo of intervention.

Collaborators and Investigators

• Sponsor: University of Missouri-Columbia
• Investigators: Principal Investigator: Camila Manrique Acevedo, MD, University of Missouri-Columbia

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2018
• Primary Completion (Actual): March 10, 2022
• Study Completion (Actual): March 10, 2022

Study Registration Dates

• First Submitted: August 16, 2018
• First Submitted That Met QC Criteria: August 23, 2018
• First Posted (Actual): August 28, 2018

Study Record Updates

• Last Update Posted (Actual): July 3, 2023
• Last Update Submitted That Met QC Criteria: June 30, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: endothelial dysfunction; type 2 diabetes; arterial stiffness; hyperuricemia
• Additional Relevant MeSH Terms: Pathologic Processes; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hyperuricemia; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antirheumatic Agents; Antimetabolites; Protective Agents; Antioxidants; Free Radical Scavengers; Gout Suppressants; Allopurinol
• Other Study ID Numbers: 2012106

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes